240 related articles for article (PubMed ID: 10466059)
1. [Immunohistochemical study of p53 and Ki-67 antigen expression in bladder carcinoma].
Yuge F; Hirakata H; Igarashi H; Kodama M; Kawata N; Takimoto Y
Hinyokika Kiyo; 1999 Jul; 45(7):453-6. PubMed ID: 10466059
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
3. The relationship of the histologic grade at the deep invasive front and the expression of Ki-67 antigen and p53 protein in oral squamous cell carcinoma.
Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Tomoyose T; Takano H; Funaki K; Fukuyama H; Takahashi T; Sakoda S
J Oral Pathol Med; 2005 Nov; 34(10):602-7. PubMed ID: 16202080
[TBL] [Abstract][Full Text] [Related]
4. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
6. Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network.
Lianes P; Charytonowicz E; Cordon-Cardo C; Fradet Y; Grossman HB; Hemstreet GP; Waldman FM; Chew K; Wheeless LL; Faraggi D
Clin Cancer Res; 1998 May; 4(5):1267-71. PubMed ID: 9607586
[TBL] [Abstract][Full Text] [Related]
7. Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer.
Kamai T; Takagi K; Asami H; Ito Y; Oshima H; Yoshida KI
Br J Cancer; 2001 May; 84(9):1242-51. PubMed ID: 11336477
[TBL] [Abstract][Full Text] [Related]
8. Tumor markers in stage P1 bladder cancer.
Stavropoulos NE; Ioachim E; Charchanti A; Michael MC; Kitsiou E; Mihailidis I; Hastazeris K; Agnantis NJ
Anticancer Res; 2001; 21(2B):1495-8. PubMed ID: 11396238
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic study of cell proliferative markers ki67, PCNA and p53 oncoprotein in bladder tumors].
Ben Rejeb A; Mahjoub A; Berraies N; Tissaoui K
Ann Urol (Paris); 2000 Aug; 34(4):240-8. PubMed ID: 10994143
[TBL] [Abstract][Full Text] [Related]
10. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of p53 and Ki-67 expression in resected or biopsy specimens of bile duct carcinoma.
Murakami M; Sasaki T; Kuwada Y; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2003; 10(5):1091-6. PubMed ID: 12883663
[TBL] [Abstract][Full Text] [Related]
12. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases.
Lin O; Cardillo M; Dalbagni G; Linkov I; Hutchinson B; Reuter VE
Mod Pathol; 2003 Dec; 16(12):1289-98. PubMed ID: 14681330
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity.
Ogura K; Habuchi T; Yamada H; Ogawa O; Yoshida O
Int J Urol; 1995 Nov; 2(5):302-8. PubMed ID: 8749948
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement.
Frank I; Cheville JC; Blute ML; Lohse CM; Karnes RJ; Weaver AL; Sebo TJ; Nehra A; Zincke H
Cancer; 2004 Oct; 101(8):1803-8. PubMed ID: 15386300
[TBL] [Abstract][Full Text] [Related]
15. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
16. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
[TBL] [Abstract][Full Text] [Related]
17. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
[TBL] [Abstract][Full Text] [Related]
18. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
20. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases.
Ro JY; Shen SS; Lee HI; Hong EK; Lee YH; Cho NH; Jung SJ; Choi YJ; Ayala AG
Am J Surg Pathol; 2008 May; 32(5):752-7. PubMed ID: 18379419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
